all india institute of ayurveda · all india institute of ayurveda (an autonomous institution under...
TRANSCRIPT
ALLINDIAINSTITUTEOFAYURVEDA(An autonomous institution under the Ministry of AYUSH, Govt. of India)
Gautampuri, Sarita Vihar, NEW DELHI
20/09/19
“Gurubhyo Namaha ………….”
“ Tameka Vaidyam Shirasa Namami…..”
EAA2019 2
Dr. Prasanth DharmarajanAssistant Professor & ConsulatantDepartment of Panchakarma All India Institute of AyurvedaGautampuri, Sarita viharNew Delhi – India
20/09/19 EAA2019 3
TOPIC
9/20/19 EAA2019 4
OBJECTIVESOF
PRESENTATION
EAA2019 20/09/19 5
ToCreateConfidenceNotTo
RaiseHighClaims.
ToCreateAwarenessAboutCVA&MS.
ToHintOn- HowToApproach
InAYURVEDAPractice
ToCreateALinkOfThoughtProcesses.
ToBePassionateAbout
Ayurveda&ToKeepLovingIt.
20/09/19 EAA2019 6
CASEREPORT- ONSTROKE(CVA)
9/20/19 EAA2019 7
AGE/SEX 54/Male
DIAGNOSIS Patient diagnosed as K/C/O Stroke, (CT Brain – Multiple lacunar infarcts)Bed ridden
SINCE 4 Days
CHIEFCOMPLAINTS
• Loss of function or deterioration of functions of left side of body(Vama Paksha Cheshta Nivriti or Karmakshya
• Heaviness in affected limb (Gurutaa)• Difficulty in Speaking(Vak Stambha)
EXAMINATION • Muscle tone - Stiff muscles• Muscle strength in right upper and lower limbs was zero • Babinski sign was positive.
PAST HISTORY Patient was on allopathic medications for Hypertension since 2 years.
PANCHAKARMAPROCEDURESADOPTED
9/20/19 EAA2019 8
S.NO. PROCEDURE DURATION
1 Rookshana (Rooksha choorna pinda svedana,Takra dhara,Kshara basti)and Talam(Rasnadi choorna withKsheerabala taila101)
1stto18thday
2 Snehapana (withKalyanaka ghritam) 19thto23rdday
3 Sarvanga abhyanga(withKottamchukkadiTaila) followedbyBashpa Svedana (withDashmoola kwatha)
24thto27thday
4 Virechana (withTrivruth Avaleha,ErandaTaila,Triphala kwatha)
28thday
ROOKSHANAPROCEDURE
9/20/19 EAA2019 9
PROCEDURE DRUGAND DURATION
RookshaChoornaPinda Svedana
TwoPottalis (each250gm)made-upofJadamayadi choorna
Thesethreeprocedureswerefollowedsimultaneouslyduringthefirst18days.25-30minofPindaSvedanafollowedby30minTakra DharaandKshara Basti.
Takra Dhara 2liters ofTakra (buttermilk)wasprocessedwith50gmeachofpowdersofMustha (Cyperus rotundus)andAmalaki(Emblica offcinalis)
Kshara Basti 320mlGomutra Arka wasmixedwith100gmeachofGuda (Jaggery)andChincha kalka (50mlpasteofTamarindusindica)and10gmeachofSaindhavaLavana and 10gm powderofShatapushpa (Anethum sowa)
ORALMEDICATIONSDURINGPANCHAKARMATREATMENT
S.NO. DRUGS NAME DOSE DURATION
1 Guduchayadi kashayam 15ml +30ml lukewarm water TID
Before food
2 Kaishor guggulu 500mg TID Before food
3 AmrutothharamKashayam+Abhyarishta+ HingvashtakChoorna
(15ml+ 15ml+5gm) +30ml lukewarm water TID
After food
4 Erand taila 10ml with lukewarm milk Bed time
20/09/19 EAA2019 11
20/09/19 EAA2019 12
20/09/19 EAA2019 13
20/09/19 EAA2019 14
OBSERVATIONS
S.NO. ASSESSMENT CRITERIA SCORING BEFORE TREATMENT
SCORING AFTER TREATMENT
1 National Institute of Health Stroke Scale (NIH-SS)
42(range from 0 to 42) 11
2 Barthel Index (BI) 35/100 75/100
3 European Stroke Scale 45/100 75/100
QOLSCALEFORSTROKE
QOLSCALE SCORINGBEFORETREATMENT
SCORING AFTERTREATMENT
STROKESPECIFICQUALITYOFLIFE(SSQOL)
75/245(rangefrom49-245)
175/245
CASEREPORT- ONMULTIPLESCLEROSIS
9/20/19 EAA2019 17
AGE/SEX 28/M, VATA PITTA PRAKRUTI
HISTORY Bed ridden – unable to move – send away from all modern hospitals with no hope on further prognosis – Diagnosed case of MS.
CHIEF COMPLAINTS • Weakness in both upper and lower limbs (Dourbalya - Kapha Kshaya & Majja Kshaya) unable to walk
• Feeling that body parts are swollen, wet (Staimitya, Gurutwa)• Spasticity & Muscle Spasm (Sankocha)• Tingling sensations(Harsha)• Feelings that body parts are tightly wrapped (Veshtana )
EXAMINATION • Lack of coordination• Changes in reflexes • Weakness in arms or legs• Spasticity in muscles
DIAGNOSIS Patient diagnosed as K/C/O Multiple Sclerosis, Demyelination,Multiple level disc protrusion
Panchakarma procedures adoptedS.NO. PROCEDURE DURATION
1 Rookshana (Rooksha choorna pinda svedana, Takradhara, Kshara basti) and Talam (Rasnadi choornawith Ksheerabala taila 101)
1st to 7th day
2 Snehapana (with Brahmi ghritam) 8th to 12th day
3 Sarvanga Abhyanga (with Bala AshwagandhadiTaila) followed by Bashpa Svedana (with Dashmoola Kwatha)
13th to 16th day
4 Virechana (with Trivruth Avaleha, Draksha Phanta) 16th day
5 Samsarjana karma 17th to 21st day
6 Kala basti Anuvasan bastiNirooha basti
22nd to 37th day
20/09/19 EAA2019 19
TREATMENTSCHEDULE(1)- ROOKSHANA
9/20/19 EAA2019 20
PROCEDURE DRUG AND DOSE
Rooksha choornaPinda Svedana
Two Pottalis (each 250gm) made-up of Jadamayadi choorna
These three procedures were followed simultaneously during the first 7 days. 25-30 min of Pinda Svedanafollowed by 30 min Takra Dharaand Kshara Basti.
Takra Dhara 2 liters of Takra (buttermilk) was processed with 50gm each of powders of Mustha(Cyperus rotundus) and Amalaki (Emblicaoffcinalis)
Kshara Basti 200ml Goumutra Arka was mixed with 50gm each of Guda (Jaggery) and Chincha kalka(50ml paste of Tamarindus indica) and 10gm each of Saindhava lavana and 10gm powder of Shatapushpa (Anethum sowa)
TREATMENT SCHEDULE (2)- BRUHMANA
Anuvasan Basti Nirooha Basti
• Masha taila (80ml) + Dhanwantaram taila (70ml)• Kapikachhu kalka (15gm)• Saindhav lavana (10gm)
• Madhu (80ml)• Saindhav lavana (10gm)
• Sneha- Kalyanak ghritam (80ml)• Kalka- Pootayavaanyaadi (30gm)• Kwatha- Balamooladi ksheerpaka
(400ml) + Majja (100ml)
KALA BASTI
20/09/19 EAA2019 21
TREATMENTSCHEDULE(3)
9/20/19 EAA2019 22
S.NO. PROCEDURE DURATION
1 Patra Pinda Svedana with Karpasasthyadi taila
These four procedures were followed simultaneously during the Kala basti. 25-30 min of Patra Pinda Svedanafollowed by 40 min Pizhichil and Shirobasti
2 Talapothichil with Ksheerbala (101) taila & Amalaki Choorna
3 Pizhichil with Ksheerbala taila + Tilataila
4 Shirobasti with Ksheerbala taila + Tilataila
TREATMENT SCHEDULE (4)• After completion of Kala basti, Nasya and Shashtika Shali
Pinda Svedana were adopted.S.NO. PROCEDURE DURATION
1 Nasya with Brahmi ghritam MukhaAbhyanga with Asanbilvadi Taila and Mridu Nadi Svedana with Dashmoolakwatha for 5min.
38th to 45th day
2 Shashtik Shali Pinda Svedana with Balamoola kwatha
38th to 45th day
20/09/19 EAA2019 23
ORALMEDICATIONSDURINGPANCHAKARMATREATMENT
9/20/19 EAA2019 24
S.NO. DRUGS NAME DOSE DURATION
1 Ashtavargam kashyam 10ml +30mllukewarm water TDS
Before food
2 Sudarshana Ghan Vati 2 Tab TDS Before food
3 Saraswatarishta+
Balarishta
(15ml+ 15ml) +30ml lukewarm water TDS
After food
4 Narasimha rasayana 1TSF with lukewarm water
Bed time
20/09/19 EAA2019 25
20/09/19 EAA2019 26
20/09/19 EAA2019 27
OBSERVATION
9/20/19 EAA2019 28
S.NO. ASSESSMENTCRITERIA
SCORINGBEFORE TREATMENT
SCORINGAFTER TREATMENT
1 Kurtz Expanded Disability Status Scale (EDSS)
6/10 8/10
2 Functional Assessment of Multiple Sclerosis (FAMS)
122/232 158/232
QOLSCALEFORMULTIPLESCLEROSIS
9/20/19 EAA2019 29
S.NO. QOL SCALE SCORINGBEFORE TREATMENT
SCORINGAFTER TREATMENT
1 MULTIPLE SCLEROSIS QUALITY OF LIFE (MSQOL)-54
22/54 42/54
2 MULTIPLE SCLEROSIS RATING SCALE REVISED (MSRS-R)
16/28 22/28
RESULTS
9/20/19
• Afterfirstweekoftreatmentpatientshowedmildreductioninpainandstiffnessinbothlowerextremities.
• Aftertwoweeksoftreatmentpainandstiffnessinbothlowerextremitiesweremoderatelyreduced.Musclepowershowedimprovementtogradeone(flickeringofmovement).
• Afterthreeweeksoftreatmentpainandstiffnessinbothlowerextremitieswereverymild.
• Kurtzke EDSSscorealsoimproved.Patientcouldwalkupto30meterswithcruches.
• Deeptendonreflexesofkneeandanklewerenormal.
• Kurtzke EDSSscoreimprovedindicatingrequirementofconstantbilateralassistance(canes,crutches,braces)andcanwalkabout20meterswithoutresting.
• Patientwasdischargedafter7weeksoftreatmentandwasaskedtocontinueoralmedicationsandapplicationofBalaAshwgandhadi taila tothewholebodyregularly.
• Heiskeepingfineandcomesforfollowupwithfathertillthehospitalwalksinsidetothehospitalalonewithoutsupport.
EAA2019 30
METABOLIC SYNDROME§ Metabolic syndrome is
characterized by cluster of risk
factors including
Ø Obesity,
Ø Insulin resistance,
Ø Hypertension,
Ø Hypertriglyceridemia &
Ø Low HDL cholesterol.
§ The Metabolic syndrome has known as an independent risk factor of stroke20/09/19 EAA2019 31
METABOLICSYNDROME
9/20/19 32
• Multiplesclerosis(MS)isthemostcommoninflammatorydemyelinatingdiseaseofthecentralnervoussystem.
• Recentresearchsuggestsanimportantplausibleroleofvasculardiseaseriskfactors(VDRFs)suchassmoking,obesity,hyperlipidemia,hypertension,diabetes,andmetabolicsyndromeonMSpathogenesis.
EAA2019
METABOLICSYNDROME
• Itisestimatedthatnearly50%ofpeoplewithMShaveatleastoneVDRFatthetimeoftheirMSdiagnosis
9/20/19 EAA2019 33
§ Stroke is the sudden death of brain cells
in a localized area due to inadequate
blood flow (infarction).
§ Stroke is the leading cause of adult
disability.
§ Sixty percent of survivors have
disabilities in arm or leg .
STROKE
20/09/19 EAA2019 34
9/20/19 EAA2019 35
CAUSESOFSTROKE
CEREBRALINFARCTION (85%)
INTRACEREBRAL HAEMORRHAGE (10%)
§ Mostly due to thromboembolic
disease secondary to
atherosclerosis in the major
extra cranial arteries.
§Usually results from rupture of a blood
vessel within the brain parenchyma: a
primary intracerebral haemorrhage.
§It may also occur with subarachnoid
haemorrhage (5%)
CLINICALFEATURESOFSTROKE
9/20/19 EAA2019 37
UnilateralWeakness SuddenWeaknessornumbnessoftheface,armorleg &progressesrapidlyinhemiplegicpattern
Speech Disturbances(Dysphasiaand Dysarthria)
Difficultyspeakingorunderstandingspeech
Visual Deficit DifficultyseeingwithoneorbotheyesAtaxia lossofbalanceorcoordinationComa faintingorunconsciousnessSevereheadachewithnoknowncause
AYURVEDAPERSPECTIVE
9/20/19
• ClinicalpresentationofStrokeissimilartothediseasePakshaghatamentionedunderVatavyadhi inAyurvedatexts.
• SymptomsofPakshaghata :• Vama/DakshinaPakshacheshtanivritiorKarmakshya– LeftorRightside,Lossoffunctionordeteriorationoffunctionsofanysideofbody
• VakStambha– DifficultyinSpeaking
EAA2019 38
PAKSHAGHATA
NIDANA(CAUSATIVE FACTORS)
VATA PRAKOPA(AGGRAVATION OF
VATA)
SIRA-SNAYU SHUSHKTA
(DRYING UP OF VESSELS)
SANDHIBANDHA VIMOKSHANA
(JOINTS BECOME LAXED AND VIGOURLESS)
PAKSHAGHATA(STROKE)
20/09/19 EAA2019 39
MULTIPLE SCLEROSIS§ Multiple sclerosis (MS)
literally means “many scars,”
§ Autoimmune disease of the CNS.
§ Characterized by chronic inflammation, demyelination, gliosis (scarring), and neuronal loss
20/09/19 EAA2019 40
MULTIPLE SCLEROSIS§ These scars, or lesions, consist mostly of dead nerve
cells, whose axons have been denuded of the myelin
sheaths
§ Risk factors for MS include vitamin D deficiency,
exposure to Epstein-Barr virus (EBV) after early
childhood, and cigarette smoking.
20/09/19 EAA2019 41
9/20/19 EAA2019 42
MULTIPLE SCLEROSISAbnormal immune system response
Inflammation in the central nervous system
Damages/destroys myelin, oligodendrocytes and Nerve fibers
Produces damaged areas (lesions or scars) along the nerve, which can be detected on MRI
Slows or halts nerve conduction – producing the neurologic signs and symptoms of MS
20/09/19 EAA2019 43
TYPES OF M.S
There are 4 types of MS
qRelapsing-remitting MS (RR-MS)
qPrimary-progressive MS (PP-MS)
qProgressive-relapsing MS (PR-MS)
qSecondary-progressive MS (SP-MS)
RELAPSING-REMITTING MS (RR-MS)
Morethan80%ofthecases
Definedclinicalexacerbationofneurologicalsymptoms
Followedbycompleteorincompleteremissionduringwhichthepersonfullyorpartiallyrecoversfromthedeficitsacquiredduringrelapse
PRIMARY-PROGRESSIVE MS (PP-MS)
10to20%ofindividualswithMSarediagnosedwithPP-MS
Gradualprogressionofthediseasefromitsonset
Nooverlappingrelapsesandremissions
PROGRESSIVE-RELAPSING MS (PR-MS)
Rare
InitiallypresentingasPP-MShowever,duringthecourseofthediseasetheindividalsdeveloptrueneurologicexacerbations
Steadyprogressionofclinicalneurologicaldamagewithsuperimposedrelapsesandremissions.
SECONDARY-PROGRESSIVE MS (SP-MS)
SP-MSischaracterizedbyasteadyprogressionofneurologicaldamagewithorwithoutsuperimposedrelapsesandminorremissions
IndividualswithSP-MSwillhaveexperiencedaperiodofRR-MS,whichmayhavelastedfrom2to40years
Anysuper-imposedrelapsesandremissionsfadeovertime
JATHARAGNIMANDYA
FORMATION OF AMA SROTOAVARODHA
GATA VATA PRAKOPA
IMPROPER NOURISHMENT OF DHATU - MAJJA DHATU
MAJJA DHATU KSHAYA & KAPHA KSHAYA
MULTIPLE SCLEROSIS
VATA FILLING THE SROTAS DEVOID
OF SNEHADI GUNA
SARVANGA VATA PRAKOPA LAKSHANA
20/09/19 EAA2019 49
CLINICALFEATURESOFMS
9/20/19 EAA2019 50
WEAKNESS OF LIMBS ; LOSS OF STRENGTH IN LIMBS AND FATIGUE
DOURBALYA (KAPHAKSHAYA & MAJJAKSHAYA)
Spasticity & Muscle Spasm Sankocha (Vata Prakopa)
Tingling sensations Harsha (Vata Prakopa)
Prickling sensations Suchivat Bhedana (Vata Prakopa)
Painful burning sensation Daha (Pittavrita Vata)
Formications, (sensation of having insects crawling on or under the skin)
Pipplikasancharan (Vata Prakopa)
feelings that body parts are swollen, wet, Staimitya (SamaVata)
Feelings that body parts are tightly wrapped Veshtana (Vata Prakopa)
CLINICALFEATURESOFMS
9/20/19 EAA2019 51
Optic Neuritis (ON) - Diminished Visual Activity Tamodarshana (Majja Kshaya)
Ataxia Kampa/Vepathu (Vata Vikara)
Bladder dysfunction; Urinary Retention, Difficulty in initiating the urine
Mutrasanga (Vata Vikara)
Constipation Vibandha (SamaVata)
Depression Manasada (Vata Vikara)
Vertigo Bhrama (Majja Kshaya)
Decreased Libido, Impotence Shukrakshaya (Majja Kshaya)
STROKE&MSASVATAVYADHI
1
Pakshaghata hasbeenmentionedunderthespectrumofVatavyadhi inAyurvedatextswithsimilarclinicalpresentationtoStroke.
2
MShasnotbeenmentionedasaseparatedisease,butmostofthesymptomsofMSaresimilartoVata Prakopa,SamaVataandMajja Kshaya Lakshana mentionedinAyurvedatexts.
YES
NO
STA
GE
1
VATA VYADHI
§ ASSESSMENT OF DOSHAVRITA VATA LAKSHANA
§ ASSESSMENT OF AMA DOSHA LAKSHANA
ROOKSHANA - ROOKSHA SVEDANA, PARISHEKA, LEPA [TILL AVRITA DOSHA & AMA LAKSHANA SUBSIDE & SAMYAK LANGHANA ATTAINED]
CHECKPOINT1
GO TO STAGE 3
20/09/19 EAA2019 53
STA
GE
2S
TAG
E 3
AVRITA DOSHA & AMA LAKSHANA SUBSIDE &
SAMYAK LANGHANA LAKSHANA OBSERVED
KOSHTHA SHUDDHI / MRIDU SAMSHODHANA
(WITH ERANDA TAILA & MILK
SHUDDHA VATA CHIKITSA
CHECKPOINT2
NoImprovement
20/09/19 EAA2019 54
STAGE 3.1
SHUDDHA VATA CHIKITSA
§ ABHYANGA§ SNIGDHA SVEDANA
(PATRAPINDA SVEDA, SHASTIKA SHALI PINDA SVEDA )
§ BRUMHANA BASTI YAPANA BASTI
§ BRUMHANA NASYA
STAGE 3.2
STAGE 3.3
STAGE 3 CHIKITSA CAN BE INCORPORATED WITH SHIROPICHU/SHIROBASTI/SHIRODHARA IN SHIROGATA VATA AVASTHA e.g.§ NEURO DEGENERARTIVE
DISEASES OF BRAIN § FACIAL PALSY§ STROKE
20/09/19 EAA2019 55
OUTCOMEOFTREATMENT
EAA2019 9/20/19 56
After2weeksofVirechana;patientwasabletomovehisrightupperlimbatelbowjointandwasabletowalkforsomedistancewithoutsupport.
1Lateronfollowupafter36dayswithcontinuationofsameinternalmedicinesshowedverygoodremissionofclinicalsymptomsandimprovedqualityoflife.
2PatientwasonTabamlodipine5mgforhypertensionduringandafterthetreatment.
3
CONCLUSION
CVA
GBS
MS
20/09/19 EAA2019 57
PACHANA
SHODHANA
BRUHMANA
DANKESCHON………..
9/20/19
EAA2019
20/09/19 EAA2019 59